In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease
Brain · 2025
DOI: 10.1093/brain/awae404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Adriana Cortés und 32 weiteren Autor:innen. Beteiligte Einrichtung: Proteored-ISCIII, Proteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona ES 31008, Spain. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, rab GTP-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation for Parkinson's Research, Michael J. Fox Foundation for Parkinson’s Research.
Abstract (Originalsprache)
Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson’s disease (L2PD) and idiopathic PD. However, pharmacodynamic readouts and progression biomarkers for clinical trials aiming for disease modification are insufficient, given that no endogenous marker reflecting enhanced kinase activity of the most common LRRK2 G2019S mutation has yet been reported in L2PD patients. Using phospho-/proteomic analyses, we assessed the impact of LRRK2-activating mutations in peripheral blood mononuclear cells from an LRRK2 clinical cohort from Spain (n = 174). The study groups encompassed G2019S L2PD patients (n = 37), non-manifesting LRRK2 mutation carriers of G2019S (here termed G2019S L2NMCs) (n = 27), R1441G L2PD patients (n = 14), R1441G L2NMCs (n = 11), idiopathic PD patients (n = 40) and healthy controls (n = 45). We identified 207 differentially regulated proteins in G2019S L2PD compared with controls (39 upregulated and 168 downregulated) and 67 in G2019S L2NMCs (10 upregulated and 57 downregulated). G2019S downregulated proteins affected the endolysosomal pathway, proteostasis and mitochondria, e.g. ATIC, RAB9A or LAMP1. At the phospho-proteome level, we observed increases in endogenous phosphorylation levels of pSer106 RAB12 in G2019S carriers, which were validated by immunoblotting after 1 year of follow-up (n = 48). Freshly collected peripheral blood mononuclear cells from three G2019S L2PD, one R1441G L2PD, one idiopathic PD and five controls (n = 10) showed strong diminishment of pSer106 RAB12 phosphorylation levels after in vitro administration of the MLi-2 LRRK2 inhibitor. Using machine learning, we identified an 18-feature G2019S phospho-/protein signature discriminating G2019S L2PD, L2NMCs and controls with 96% accuracy that was correlated with disease severity, i.e. UPDRS-III motor scoring. Using easily accessible peripheral blood mononuclear cells from a LRRK2 clinical cohort, we identified elevated levels of pSer106 RAB12 as an endogenous biomarker of G2019S carriers. Our data suggest that monitoring pSer106 RAB12 phosphorylation could be a relevant biomarker for tracking LRRK2 activation, particularly in G2019S carriers. Future work might determine whether pSer106 RAB12 could help with patient enrichment and monitoring drug efficacy in LRRK2 clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Proteored-ISCIII, Proteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona ES 31008, Spain.
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 5EH, UK.
- Lab for Parkinson's & Other Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Insti…
- Neurology Service, University Hospital Marqués de Valdecilla-IDIVAL, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Santander ES 39008, Spain.
- Department of Neurology, Donostia University Hospital, Biogipuzkoa Health Research Institute, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), San Sebastián ES 20014, Spain.
- In Silico Medicinal Chemistry, Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RP, UK.
ORCID-Profile: Cristina Malagelada, Mario Ezquerra, Rubén Fernández-Santiago
Förderung
- Michael J. Fox Foundation for Parkinson's Research
- Michael J. Fox Foundation for Parkinson’s Research
Zitieren
APA
Cortés, A., Phung, T. K., de Mena, L., Garrido, A., Infante, J., Ruíz-Martínez, J., Galmés-Ordinas, M. À., Glendinning, S., Pérez, J., Roig, A., Soto, M., Cosgaya, M., Ravasi, V., Fernández, M., Rubiano-Castro, A., Díaz, R., Hernández-Eguiazu, H., Sánchez-Quintana, C., Vinagre-Aragón, A., …, & Fernández-Santiago, R. (2025). In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease. Brain. https://doi.org/10.1093/brain/awae404
Vancouver
Cortés A, Phung TK, de Mena L, Garrido A, Infante J, Ruíz-Martínez J, et al. In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease. Brain. 2025. doi:10.1093/brain/awae404
BibTeX
@article{Corts2025,
author = {Cortés, Adriana and Phung, Toan K and de Mena, Lorena and Garrido, Alicia and Infante, Jon and Ruíz-Martínez, Javier and Galmés-Ordinas, Miquel À and Glendinning, Sophie and Pérez, Jesica and Roig, Ana and Soto, Marta and Cosgaya, Marina and Ravasi, Valeria and Fernández, Manel and Rubiano-Castro, Alejandro and Díaz, Ramón and Hernández-Eguiazu, Haizea and Sánchez-Quintana, Coro and Vinagre-Aragón, Ana and Mondragón, Elisabet and Croitoru, Ioana and Rivera-Sánchez, María and Corrales-Pardo, Andrea and Sierra, María and Tolosa, Eduardo and Malagelada, Cristina and Nirujogi, Raja S and Fernández-Irigoyen, Joaquín and Santamaría, Enrique and Alessi, Dario R and Martí, María J and Ezquerra, Mario and Fernández-Santiago, Rubén},
title = {In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awae404}
}
EUVIMED